Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

165.12 +0.65 (+0.40%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,924,814
Open 164.89
Bid (Size) 164.70 (1)
Ask (Size) 165.12 (10)
Prev. Close 164.47
Today's Range 163.93 - 165.29
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.88%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
These companies' longtime shareholders have generally been rewarded. 
Via The Motley Fool
Three Safe Dividend Kings to Weather Any Storm
Income investors should focus on stocks with solid yields, sustainable payouts, and strong business models. One way to achieve this is by investing in safe dividend kings. 
Via Talk Markets

Performance

YTD
+3.22%
+3.22%
1 Month
-0.62%
-0.62%
3 Month
+6.74%
+6.74%
6 Month
+11.64%
+11.64%
1 Year
+8.40%
+8.40%

More News

Read More
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson’s Medtech Segment Shines With Impressive Q3 Growth
Via Talk Markets
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Via Chartmill
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Via The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Via The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Via Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Via The Motley Fool
Are JNJ’s Mergers And Acquisitions Weighing Down Company’s Performance?
Via Talk Markets
Cancer Drugs Propel J&J Beyond Wall Street Estimates
Via Benzinga
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Via Benzinga
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
Via Benzinga
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
Via Benzinga
Johnson & Johnson Earnings Top; Dow Giant Works Toward Buy Point
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.